Amgen said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make i(...)

Prof Nancy Hopkins: chaired first committee on women faculty at MIT’s school of science.

Achieving a gender balance in higher education requires a sustained commitment that can last for years. Balance can be reached however, as shown by a (...)

Total spending on drugs will hit $1.06 trillion this year, an increase of 7 per cent over 2013 levels

Pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sc(...)

What if Alexander Fleming’s funding been restricted to a ‘time-locked deliverable’?

The philosopher Georg Wilhelm Friedrich Hegel (1770-1831) found himself at the centre of an unlikely political ruckus in Australia this time last y(...)

Following on from Sunday’s stress test results, AIB was down by 5 per cent to 10 cents. Photograph:  Cyril Byrne

European shares rose yesterday, reversing the previous session’s dip as better-than-expected results from a number of blue-chips including pharma gro(...)

Pfizer tightened its full-year earnings forecast to between $2.23 and $2.27 per share from its prior outlook of $2.20 to $2.30

Pfizer reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets(...)

Mark Ferguson, Director of of SFI Science Foundation Ireland, photographed in the Science Gallery, Dublin. Photograph: Bryan O’Brien/Irish Times

More than €1.7 million in funding has been made available to support twenty new high-potenial industry-academia partnerships. The funding, whic(...)

Mark Ferguson, Director of of SFI Science Foundation Ireland, photographed in the Science Gallery, Dublin. Photograph: Bryan O’Brien/Irish Times

More than €1.7 million in funding has been made available to support twenty new high-potenial industry-academia partnerships.The funding, which is bei(...)

France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe’s second(...)

 “The decision of certain public authorities to promote off-label medicines raises the question as to what would happen if the use of such drugs gave rise to patient safety concerns. Given the negative consequences for private companies which promote off-label medicines, it would be interesting to see whether these public authorities would face similar liability.”

Concerns raised during the recent inquest into the tragic death of Bimbo Onanuga have again highlighted the potential difficulties arising from the u(...)